Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 100 of the 101 references it cites were found in a registry or an index.

Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies

Open access

Abstract

Chemotherapy and targeted therapy are the major treatments for gastric cancer (GC), but drug resistance limits its effectiveness. Here, we profile the proteome of 206 tumor tissues from patients with GC undergoing either chemotherapy or anti-HER2-based therapy. Proteome-based classification reveals four subtypes (G-I-G-IV) related to different clinical and molecular features. MSI-sig high GC patients benefit from docetaxel combination treatment, accompanied by anticancer immune response. Further study reveals patients with high T cell receptor signaling respond to anti-HER2-based therapy; while activation of extracellular matrix/PI3K-AKT pathway impair anti-tumor effect of trastuzumab. We observe CTSE functions as a cell intrinsic enhancer of chemosensitivity of docetaxel, whereas TKTL1 functions as an attenuator. Finally, we develop prognostic models with high accuracy to predict therapeutic response, further validated in an independent validation cohort. This study provides a rich resource for investigating the mechanisms and indicators of chemotherapy and targeted therapy in GC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-33282-0

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Summary of the proteomic analysis of gastric cancer. a The proteomics workflow involved three modules: cohort construction (including discovery cohort and validation cohort), proteomic profiling, and data analysis. The proteins were trypsin-digested, and then analyzed in a single-run (75 min) high-performance liquid chromatography mass spectrometry (HPLC-MS) using a Q Exactive HF-X Hybrid Quadrupole-Orbitrap Mass Spectrometer. MS proteomics data were quantified with the Firmiana proteomics workstation, and PRM-MS proteomics data were quantified with Skyline-daily. b The gastric cancer (GC) cohort included three clinical therapy subcohorts: DOS, XELOX, and HER2. Clinical parameters are indicated in the heatmap. c Kaplan–Meier plots show significant differences between the sensitive group (S) and non-sensitive group (NS) in overall survival (OS). P-value is calculated by two-sided log rank test. d Overview of the proteomic profile of patients with GC. Shown are the dynamic range of the protein identification of each sample according to the descending sort of protein abundance in this sample. Range: 6369–8119 proteins. Proteins were quantified as a normalized intensity-based fraction of total (FOT) value and log10 transformed. The highest- and lowest-abundance proteins are shown in the box. e Venn diagram showing the protein overlap of S and NS. Number of proteins were quantified in S and NS (two-sided Student’s t test, P = 0.228). n (S) = 82, and n (NS) = 103 biologically independent samples examined. Data are shown as mean values ± SD. P < 0.05 considered statistically significant. Source data are provided as a Source Data file.
Fig. 1 Summary of the proteomic analysis of gastric cancer. a The proteomics workflow involved three modules: cohort construction (including discovery cohort and validation cohort), proteomic profiling, and data analysis. The proteins were trypsin-digested, and then analyzed in a single-run (75 min) high-performance liquid chromatography mass spectrometry (HPLC-MS) using a Q Exactive HF-X Hybrid Quadrupole-Orbitrap Mass Spectrometer. MS proteomics data were quantified with the Firmiana proteomics workstation, and PRM-MS proteomics data were quantified with Skyline-daily. b The gastric cancer (GC) cohort included three clinical therapy subcohorts: DOS, XELOX, and HER2. Clinical parameters are indicated in the heatmap. c Kaplan–Meier plots show significant differences between the sensitive group (S) and non-sensitive group (NS) in overall survival (OS). P-value is calculated by two-sided log rank test. d Overview of the proteomic profile of patients with GC. Shown are the dynamic range of the protein identification of each sample according to the descending sort of protein abundance in this sample. Range: 6369–8119 proteins. Proteins were quantified as a normalized intensity-based fraction of total (FOT) value and log10 transformed. The highest- and lowest-abundance proteins are shown in the box. e Venn diagram showing the protein overlap of S and NS. Number of proteins were quantified in S and NS (two-sided Student’s t test, P = 0.228). n (S) = 82, and n (NS) = 103 biologically independent samples examined. Data are shown as mean values ± SD. P < 0.05 considered statistically significant. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 2 Proteomic subtyping of the gastric cancer cohort and its association with clinical characteristics. a The heatmap depicts the relative abundance (Z score of FOT) of the signature proteins in four subtypes of 179 GC samples. Biological functions related to these signature proteins are denoted on the right. b The association of four proteomic subtypes with clinical characteristics (including gender, grade, Lauren’s type, primary site, HER2 status, RECIST, and tumor purity, etc.) are annotated with *P-values (two-sided Fisher’s exact test for categorical variables, and two-way ANOVA test for continuous variables). c The Kaplan–Meier curves of overall survival (OS) of each proteomic subtype (G-I, n = 28; G-II, n = 56; G-III, n = 75; and G-IV, n = 20). P-value is calculated by two-sided log rank test. d Left panel: Bubble plot showing the KEGG pathway enrichment (two-sided Fisher’s exact test) of each proteomic subtype. Right panel: Diagram illustrating the differentially expressed signatures and signaling cascades involved in G-I to G-IV. The little heatmap under each protein depicted the Z score of average protein abundance in each proteomic subtype. Red, upregulated proteins; blue, downregulated proteins. e The correlation of the extracellular matrix proteins and different drugs, including 5-FU, OXA, and DOC. The drug sensitivity (half maximal inhibitory concentration [IC50]) of gastric cancer cell lines was from the Cancer Dependency Map Project (DepMap). P-values are derived from two-sided Pearson’s correlation test. f Dose-response curves of MKN45 and MGC803 cell lines overexpressing THSD4 after 72-h treatments with DOC, OXA, and 5FU. Barplots showing the comparison of IC50 values in each group. Bars represent the mean of n = 3 independent experiments with error bars indicating SD. P-values are calculated using two-sided Student’s t test. g Boxplot showing the differential expression of ECM proteins validated by PRM assay (two-sided Wilcoxon rank-sum test, n = 10 biologically independent samples per group). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). Source data are provided as a Source Data file.
Fig. 2 Proteomic subtyping of the gastric cancer cohort and its association with clinical characteristics. a The heatmap depicts the relative abundance (Z score of FOT) of the signature proteins in four subtypes of 179 GC samples. Biological functions related to these signature proteins are denoted on the right. b The association of four proteomic subtypes with clinical characteristics (including gender, grade, Lauren’s type, primary site, HER2 status, RECIST, and tumor purity, etc.) are annotated with *P-values (two-sided Fisher’s exact test for categorical variables, and two-way ANOVA test for continuous variables). c The Kaplan–Meier curves of overall survival (OS) of each proteomic subtype (G-I, n = 28; G-II, n = 56; G-III, n = 75; and G-IV, n = 20). P-value is calculated by two-sided log rank test. d Left panel: Bubble plot showing the KEGG pathway enrichment (two-sided Fisher’s exact test) of each proteomic subtype. Right panel: Diagram illustrating the differentially expressed signatures and signaling cascades involved in G-I to G-IV. The little heatmap under each protein depicted the Z score of average protein abundance in each proteomic subtype. Red, upregulated proteins; blue, downregulated proteins. e The correlation of the extracellular matrix proteins and different drugs, including 5-FU, OXA, and DOC. The drug sensitivity (half maximal inhibitory concentration [IC50]) of gastric cancer cell lines was from the Cancer Dependency Map Project (DepMap). P-values are derived from two-sided Pearson’s correlation test. f Dose-response curves of MKN45 and MGC803 cell lines overexpressing THSD4 after 72-h treatments with DOC, OXA, and 5FU. Barplots showing the comparison of IC50 values in each group. Bars represent the mean of n = 3 independent experiments with error bars indicating SD. P-values are calculated using two-sided Student’s t test. g Boxplot showing the differential expression of ECM proteins validated by PRM assay (two-sided Wilcoxon rank-sum test, n = 10 biologically independent samples per group). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 3 The application of FDGC subtyping algorithm in multiple independent cohorts, and the association of MSI/MSS characteristics with clinical outcomes. a Sankey diagram indicating the comparison of FDGC subtype and BPRC subtype or EOGC subtype. b Sankey diagram and barplot indicating the comparison of FDGC subtype and ACRG subtype. Survival analysis of ACRG cohort classified by FDGC subtyping (two-sided log rank test). c Heatmap of CNV GI (copy number variation genomic instability index), MSI-H assay status, mutations, and MSI/MSS-sig (microsatellite instability/microsatellite stability gene expression signatures assessment) of ACRG cohort classified by FDGC subtyping (upper). Heatmap of MSI/MSS-sig of FDGC subtype (bottom). P-values are calculated by two-sided Fisher’s exact test (categorical variables) and two-way ANOVA test (continuous variables). d The association of MSI/MSS-sig level with OS in ACRG and FDGC cohorts (two-sided log rank test). e Heatmap illustrating significantly differential expressed proteins in MSI/MSS-sig high and low group (two-sided Wilcoxon rank-sum test). f Heatmap illustrating down-regulated proteins in G-IV compared with other subtypes (Kruskal-Wallis test). g Heatmap illustrating the dominant cell type compositions of G-II, G-III, and G-IV (two-sided Student’s t test). h Boxplot showing the xCell score of Macrophages M1 and monocytes among four proteomic subtypes (two-sided Student’s t test). n (G-I) = 28, n (G-II) = 56, n (G-III) = 75, n (G-IV) = 20 biologically independent samples examined. Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). i Correlation between MSI/MSS-sig with Macrophages M1 and monocytes (two-sided Pearson’s correlation test). j The association of Macrophages M1 and monocytes with OS in FDGC and ACRG cohorts (two-sided Gehan-Breslow-Wilcoxon or two-sided log rank test). k The abundance of Macrophages M1 markers in MSI/MSS-sig high and low groups (two-sided Wilcoxon rank-sum test). l Correlation between IL18 abundance with MSI/MSS-sig (two-sided Pearson’s correlation test), and survival analysis of IL18 expression with OS (two-sided log rank test). m Diagram illustrating the potential association between MSS/MSI characteristics with drug response. *P < 0.05 is considered statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Source data are provided as a Source Data file.
Fig. 3 The application of FDGC subtyping algorithm in multiple independent cohorts, and the association of MSI/MSS characteristics with clinical outcomes. a Sankey diagram indicating the comparison of FDGC subtype and BPRC subtype or EOGC subtype. b Sankey diagram and barplot indicating the comparison of FDGC subtype and ACRG subtype. Survival analysis of ACRG cohort classified by FDGC subtyping (two-sided log rank test). c Heatmap of CNV GI (copy number variation genomic instability index), MSI-H assay status, mutations, and MSI/MSS-sig (microsatellite instability/microsatellite stability gene expression signatures assessment) of ACRG cohort classified by FDGC subtyping (upper). Heatmap of MSI/MSS-sig of FDGC subtype (bottom). P-values are calculated by two-sided Fisher’s exact test (categorical variables) and two-way ANOVA test (continuous variables). d The association of MSI/MSS-sig level with OS in ACRG and FDGC cohorts (two-sided log rank test). e Heatmap illustrating significantly differential expressed proteins in MSI/MSS-sig high and low group (two-sided Wilcoxon rank-sum test). f Heatmap illustrating down-regulated proteins in G-IV compared with other subtypes (Kruskal-Wallis test). g Heatmap illustrating the dominant cell type compositions of G-II, G-III, and G-IV (two-sided Student’s t test). h Boxplot showing the xCell score of Macrophages M1 and monocytes among four proteomic subtypes (two-sided Student’s t test). n (G-I) = 28, n (G-II) = 56, n (G-III) = 75, n (G-IV) = 20 biologically independent samples examined. Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). i Correlation between MSI/MSS-sig with Macrophages M1 and monocytes (two-sided Pearson’s correlation test). j The association of Macrophages M1 and monocytes with OS in FDGC and ACRG cohorts (two-sided Gehan-Breslow-Wilcoxon or two-sided log rank test). k The abundance of Macrophages M1 markers in MSI/MSS-sig high and low groups (two-sided Wilcoxon rank-sum test). l Correlation between IL18 abundance with MSI/MSS-sig (two-sided Pearson’s correlation test), and survival analysis of IL18 expression with OS (two-sided log rank test). m Diagram illustrating the potential association between MSS/MSI characteristics with drug response. *P < 0.05 is considered statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 4 The differential expression of proteins and signaling pathways in sensitive and non-sensitive groups of therapy subcohorts. a The association of MSI/MSS-sig level with OS in DOS and XELOX subcohorts (two-sided log rank test). b Bubble plot showing the KEGG pathway enrichment (two-sided Fisher’s exact test) of DSG, DNSG, XSG, and XNSG groups. c, d, k The GSEA enrichment analysis of TCR signaling pathway in DOS (c), XELOX (d, n (S) = 25, n (NS) = 20), XELOX of BPRC cohort (k), and XELOX + HER2 subcohorts, respectively (left). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). The survival analysis of ssGSEA TCR signaling pathway score with OS in these subcohorts (two-sided log rank test) (right). e, f, l Heatmap illustrating significantly differential cell type compositions between sensitive and non-sensitive groups of these subcohorts (two-sided Student’s t test). g ICD prediction score of 31 anticancer drugs from NCI library. h The overlap of upregulated proteins in DSG and XNSG, and the KEGG pathway enrichment (two-sided Fisher’s exact test) of these overlapped proteins. i Cox analysis (two-sided Cox test) of the proteins involved in immune modulation and ErbB2/ErbB3 signaling pathway with disease-free survival (DFS). The little boxes indicate the DFS hazard ratios. j Dose-response curves of NCI-N87 cells after 72-h treatments with XELOX, trastuzumab, and combination of trastuzumab and XELOX. The comparison of IC50 values of different therapies (two-sided Student’s t test). Bars represent the mean of n = 3 independent experiments with error bars indicating SD. m The qualification of CD4 and CD8 stained by immunohistochemistry (IHC) in representative examples in the XELOX and XELOX + HER2 subcohorts. Data are analyzed by two-sided Student’s t test and shown as mean ± SD (n = 3 independent experiments). n Diagram showing the potential connection of immune characteristics and the therapy response. Source data are provided as a Source Data file.
Fig. 4 The differential expression of proteins and signaling pathways in sensitive and non-sensitive groups of therapy subcohorts. a The association of MSI/MSS-sig level with OS in DOS and XELOX subcohorts (two-sided log rank test). b Bubble plot showing the KEGG pathway enrichment (two-sided Fisher’s exact test) of DSG, DNSG, XSG, and XNSG groups. c, d, k The GSEA enrichment analysis of TCR signaling pathway in DOS (c), XELOX (d, n (S) = 25, n (NS) = 20), XELOX of BPRC cohort (k), and XELOX + HER2 subcohorts, respectively (left). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). The survival analysis of ssGSEA TCR signaling pathway score with OS in these subcohorts (two-sided log rank test) (right). e, f, l Heatmap illustrating significantly differential cell type compositions between sensitive and non-sensitive groups of these subcohorts (two-sided Student’s t test). g ICD prediction score of 31 anticancer drugs from NCI library. h The overlap of upregulated proteins in DSG and XNSG, and the KEGG pathway enrichment (two-sided Fisher’s exact test) of these overlapped proteins. i Cox analysis (two-sided Cox test) of the proteins involved in immune modulation and ErbB2/ErbB3 signaling pathway with disease-free survival (DFS). The little boxes indicate the DFS hazard ratios. j Dose-response curves of NCI-N87 cells after 72-h treatments with XELOX, trastuzumab, and combination of trastuzumab and XELOX. The comparison of IC50 values of different therapies (two-sided Student’s t test). Bars represent the mean of n = 3 independent experiments with error bars indicating SD. m The qualification of CD4 and CD8 stained by immunohistochemistry (IHC) in representative examples in the XELOX and XELOX + HER2 subcohorts. Data are analyzed by two-sided Student’s t test and shown as mean ± SD (n = 3 independent experiments). n Diagram showing the potential connection of immune characteristics and the therapy response. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 5 The differential expression of proteins and signaling pathways in HSG/HNSG. a Kaplan–Meier plots show significant differences between the sensitive group (S) and non-sensitive group (NS) in overall survival (OS) (upper) and progression-free survival (PFS) (bottom) in the HER2 subcohort (two-sided log rank test). b Boxplot showing the ERBB2 expression in HSG (n = 32) and HNSG (n = 37) (two-sided Wilcoxon rank-sum test) (upper). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). Cox analysis (two-sided Cox test) of ERBB2 with OS (bottom). c Heatmap showing the abundance of differentially expressed proteins in HSG and HNSG. d Pathway alterations in HSG and HNSG (two-sided Fisher’s exact test). e The GSEA enrichment analysis of ECM in HER2 subcohort (Nominal P value, calculated as Phenotype-based permutation test). The survival analysis of ssGSEA ECM pathway score with OS in HER2 subcohort (two-sided log rank test). f Heatmap illustrating the abundance of ECM proteins in HER2 subcohort and five gastric cancer cells (two-sided Wilcoxon rank-sum test). g, h Left panel: Correlation of ECM pathway score (g) and PI3K-AKT pathway score (h) with its downstream pathway assessed by ssGSEA (two-sided Pearson’s correlation test). Right panel: Heatmap illustrating the protein abundance of PI3K-AKT pathway (g) and apoptosis (h) related proteins (two-sided Wilcoxon rank-sum test). i Dose-response curves of NCI-N87 cells after 72-h treatments with buparlisib (BUP), trastuzumab (TRA), and combination of trastuzumab and buparlisib with a ratio of 1:1. IC50, half-maximal inhibitory concentration. The comparison of IC50 values of different therapies (two-sided Student’s t test). Bars represent the mean of n = 3 independent experiments with error bars indicating SD. j Diagram showing the potential mechanism of resistance to anti-HER2 targeted therapy. k The decision-making strategy for the GC therapy. *P < 0.05 is considered statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Source data are provided as a Source Data file.
Fig. 5 The differential expression of proteins and signaling pathways in HSG/HNSG. a Kaplan–Meier plots show significant differences between the sensitive group (S) and non-sensitive group (NS) in overall survival (OS) (upper) and progression-free survival (PFS) (bottom) in the HER2 subcohort (two-sided log rank test). b Boxplot showing the ERBB2 expression in HSG (n = 32) and HNSG (n = 37) (two-sided Wilcoxon rank-sum test) (upper). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). Cox analysis (two-sided Cox test) of ERBB2 with OS (bottom). c Heatmap showing the abundance of differentially expressed proteins in HSG and HNSG. d Pathway alterations in HSG and HNSG (two-sided Fisher’s exact test). e The GSEA enrichment analysis of ECM in HER2 subcohort (Nominal P value, calculated as Phenotype-based permutation test). The survival analysis of ssGSEA ECM pathway score with OS in HER2 subcohort (two-sided log rank test). f Heatmap illustrating the abundance of ECM proteins in HER2 subcohort and five gastric cancer cells (two-sided Wilcoxon rank-sum test). g, h Left panel: Correlation of ECM pathway score (g) and PI3K-AKT pathway score (h) with its downstream pathway assessed by ssGSEA (two-sided Pearson’s correlation test). Right panel: Heatmap illustrating the protein abundance of PI3K-AKT pathway (g) and apoptosis (h) related proteins (two-sided Wilcoxon rank-sum test). i Dose-response curves of NCI-N87 cells after 72-h treatments with buparlisib (BUP), trastuzumab (TRA), and combination of trastuzumab and buparlisib with a ratio of 1:1. IC50, half-maximal inhibitory concentration. The comparison of IC50 values of different therapies (two-sided Student’s t test). Bars represent the mean of n = 3 independent experiments with error bars indicating SD. j Diagram showing the potential mechanism of resistance to anti-HER2 targeted therapy. k The decision-making strategy for the GC therapy. *P < 0.05 is considered statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 6 The construction and validation of predictive classifiers. a Diagram describing a construction and validation of the predictive modeling for sensitive (S) and non-sensitive (NS) groups. b The discovery cohort: Classification error matrix using logistic regression classifier of 80% training set and 20% testing set in DOS, XELOX, and HER2 subcohorts. The number of samples identified is noted in each box. c Heatmap showing differential expression of DSG/DNSG-sig, XSG/XNSG-sig, and HSG/HNSG-sig based on PRM quantification in an independent cohort (validation cohort) composed of 60 GC patients (two-sided Wilcoxon rank-sum test). Source data are provided as a Source Data file.
Fig. 6 The construction and validation of predictive classifiers. a Diagram describing a construction and validation of the predictive modeling for sensitive (S) and non-sensitive (NS) groups. b The discovery cohort: Classification error matrix using logistic regression classifier of 80% training set and 20% testing set in DOS, XELOX, and HER2 subcohorts. The number of samples identified is noted in each box. c Heatmap showing differential expression of DSG/DNSG-sig, XSG/XNSG-sig, and HSG/HNSG-sig based on PRM quantification in an independent cohort (validation cohort) composed of 60 GC patients (two-sided Wilcoxon rank-sum test). Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 7 Effect of CTSE and TKTL1 overexpression on anticancer activity of DOS and XELOX in gastric cancer cell lines MKN45 and MGC803. a. b Effect of CTSE overexpression on proliferation in gastric cancer (GC) cell lines (MKN45 and MGC803, n = 3 independent experiments, two-sided Student’s t test, mean ± SD). c–e Dose-response curves of MKN45 and MGC803 cell lines overexpressing CTSE after 72-h treatments with DOS, XELOX, and DOC. IC50, half-maximal inhibitory concentration. *P-values are calculated using two-sided Student’s t test. Barplots showing the comparison of IC50 values in each group. f, g KEGG pathway analysis showing the differential function in the CTSE group with or without DOC treatment (two-sided Fisher’s exact test). h Immunoblot analysis of soluble alpha-tubulin and soluble beta-tubulin in MKN45 cells after DOC treatment, and the normalization of qualified western blots (n = 3 independent experiments, two-sided Student’s t test, mean ± SD). i, j Effect of TKTL1 overexpression on MKN45 and MGC803 cell proliferation (n = 3 independent experiments, two-sided Student’s t test, mean ± SD). k–m Dose-response curves of MKN45 and MGC803 cell lines overexpressing TKTL1 after 72-h treatments with DOS, XELOX, and DOC (n = 3 independent experiments, two-sided Student’s t test, mean ± SD). IC50, half-maximal inhibitory concentration. Barplots showing the comparison of IC50 values in each group. n, o Chromosome segregation defects (n) and percentage of aneuploid cells (o) in DOC-treated MKN45 cells with or without TKTL1 overexpression. The left panel shows the representative results. The scale bar indicates 10 μm. The right panel shows the statistical results from n = 3 independent experiments in the MKN45 cells (two-sided Student’s t test, mean ± SD). p Schematic illustration indicating how CTSE inducts microtubule stabilization, and how TKTL1 induces abnormal chromosome segregation. Bars represent the mean of n = 3 independent experiments with error bars indicating SD (for c–e, h, k–m, n–o). Source data are provided as a Source Data file.
Fig. 7 Effect of CTSE and TKTL1 overexpression on anticancer activity of DOS and XELOX in gastric cancer cell lines MKN45 and MGC803. a. b Effect of CTSE overexpression on proliferation in gastric cancer (GC) cell lines (MKN45 and MGC803, n = 3 independent experiments, two-sided Student’s t test, mean ± SD). c–e Dose-response curves of MKN45 and MGC803 cell lines overexpressing CTSE after 72-h treatments with DOS, XELOX, and DOC. IC50, half-maximal inhibitory concentration. *P-values are calculated using two-sided Student’s t test. Barplots showing the comparison of IC50 values in each group. f, g KEGG pathway analysis showing the differential function in the CTSE group with or without DOC treatment (two-sided Fisher’s exact test). h Immunoblot analysis of soluble alpha-tubulin and soluble beta-tubulin in MKN45 cells after DOC treatment, and the normalization of qualified western blots (n = 3 independent experiments, two-sided Student’s t test, mean ± SD). i, j Effect of TKTL1 overexpression on MKN45 and MGC803 cell proliferation (n = 3 independent experiments, two-sided Student’s t test, mean ± SD). k–m Dose-response curves of MKN45 and MGC803 cell lines overexpressing TKTL1 after 72-h treatments with DOS, XELOX, and DOC (n = 3 independent experiments, two-sided Student’s t test, mean ± SD). IC50, half-maximal inhibitory concentration. Barplots showing the comparison of IC50 values in each group. n, o Chromosome segregation defects (n) and percentage of aneuploid cells (o) in DOC-treated MKN45 cells with or without TKTL1 overexpression. The left panel shows the representative results. The scale bar indicates 10 μm. The right panel shows the statistical results from n = 3 independent experiments in the MKN45 cells (two-sided Student’s t test, mean ± SD). p Schematic illustration indicating how CTSE inducts microtubule stabilization, and how TKTL1 induces abnormal chromosome segregation. Bars represent the mean of n = 3 independent experiments with error bars indicating SD (for c–e, h, k–m, n–o). Source data are provided as a Source Data file.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 101 references

Cited by

See all 80

Metadata

Authors
Li, Y., Xu, C., Wang, B., Xu, F., Ma, F., Qu, Y., Jiang, D., Li, K., Feng, J., Tian, S., Wu, X., Wang, Y., Liu, Y., Qin, Z., Liu, Y., Qin, J., Song, Q., Zhang, X., Sujie, A., Huang, J., Liu, T., Shen, K., Zhao, J.-Y., Hou, Y., & Ding, C.
Affiliations
  • Fudan University (CN)
  • Henan Normal University (CN)
  • Shanghai Medical College of Fudan University (CN)
  • Shanghai Jiao Tong University (CN)
Corresponding author
  • Liu, Tianshu
  • Shen, Kuntang
  • Zhao, Jian-Yuan
  • Hou, Yingyong
  • Ding, Chen
Venue
Nature Communications
Published
2022-09-29
Volume
13
Issue
1
Pages
5723-5723
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4297998181
Cited by
80
References
101
Citations by year
2026: 13 · 2025: 29 · 2024: 23 · 2023: 15
FWCI
10.81
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Shanghai Science and Technology Development Foundation (19MC1911000)
  • National Natural Science Foundation of China (31972933, 2018YFA0507501, 2016YFA0502500, 19MC1911000, 2017SHZDZX01, 31700682, 31770886)
  • China Postdoctoral Science Foundation (2017SHZDZX01, 2020T130114, 2019M651268)
  • Science and Technology Commission of Shanghai Municipality (2020YFE0201600, 2017SHZDZX01)
  • National Key Research and Development Program of China (2017YFA0505102, 2020YFE0201600, 2016YFA0502500, 2018YFA0507501, 2017YFC0908404, 2018YFE0201603, 2017SHZDZX01, 2017YFA0505101)
Topics
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
  • Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords
gastric cancer, proteomic profiling, chemotherapy response, targeted therapy, HER2-targeted therapy, trastuzumab, docetaxel, drug resistance, tumor subtypes, T cell receptor signaling, extracellular matrix, PI3K/Akt signaling, TKTL1, chemosensitivity, prognostic model, treatment response prediction
MeSH terms
Trastuzumab, Docetaxel, Humans, Receptors, Antigen, T-Cell, Stomach Neoplasms, Transketolase, Phosphatidylinositol 3-Kinases, Proteome, Proteomics, Proto-Oncogene Proteins c-akt

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies. https://app.cochat.ai/papers/10.1038/s41467-022-33282-0
The paper
Li, Y., Xu, C., Wang, B., Xu, F., Ma, F., Qu, Y., Jiang, D., Li, K., Feng, J., Tian, S., Wu, X., Wang, Y., Liu, Y., Qin, Z., Liu, Y., Qin, J., Song, Q., Zhang, X., Sujie, A., . . . Ding, C. (2022). Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies. Nature Communications. https://doi.org/10.1038/s41467-022-33282-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.